heptapeptide comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-03-27. Where a claim depends on a specific study, the study is described rather than over-claimed.
Tuftsin, the parent structure, is a naturally occurring immunomodulatory tetrapeptide released from the Fc region of immunoglobulin G by spleen enzymes. Selank extends this four-residue sequence with three additional amino acids. The stated rationale is that the added tail slows enzymatic breakdown and may influence receptor interactions. How the full heptapeptide behaves at the molecular level is not firmly established, and proposed mechanisms often involve indirect modulation of neurotransmitter or immune signaling rather than a single defined target.
Selank is a synthetic heptapeptide developed in Russia. Its sequence is Thr-Lys-Pro-Arg-Pro-Gly-Pro, a seven-residue chain built around the natural tetrapeptide tuftsin. Researchers at the Institute of Molecular Genetics of the Russian Academy of Sciences first described the compound in the mid-1990s. The design combined the tuftsin core with an added Pro-Gly-Pro tail, a modification intended to extend the molecule's stability in biological fluids. Published work on the peptide has appeared mainly in Russian-language journals.
Pharmacokinetic data are sparse and largely derived from animal work. After intranasal administration the peptide appears in plasma within minutes, and reported half-lives are short, on the order of minutes to tens of minutes. Degradation proceeds through ordinary proteolytic cleavage into constituent amino acids and smaller fragments. Direct evidence that intact Selank reaches brain tissue in meaningful amounts is limited, and the extent of blood-brain barrier penetration is debated. Some authors argue that fragments, not the parent peptide, carry much of the observed activity.
Published clinical work is concentrated in Russian-language journals and generally involves small samples without independent replication. Systematic reviews in English note the shortage of randomised, placebo-controlled trials and the difficulty of verifying methods from translated reports. Outcome measures vary between studies, which complicates pooling of results. Interest in the compound as a cognitive or anxiolytic agent therefore rests on a thinner evidence base than the volume of citations suggests. Replication in well-powered trials with preregistered endpoints would be needed before firm conclusions about efficacy can be drawn.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic heptapeptide | Modeled on tuftsin |
| Amino acid sequence | Thr-Lys-Pro-Arg-Pro-Gly-Pro | Seven residues |
| Approximate molecular mass | Around 750 Da | Depends on counter-ion and hydration |
| Common forms | Lyophilized powder | Also described as aqueous solution |
| Primary origin of research | Russian laboratories | Mid-1990s onward |
Selank is studied chiefly as an animal-model anxiolytic with proposed secondary effects on memory and immune signaling. Reported mechanisms include modulation of the GABA-A receptor complex, inhibition of enkephalin-degrading enzymes, and shifts in monoamine turnover within limbic structures. Some experiments describe increased expression of brain-derived neurotrophic factor in the hippocampus after repeated dosing. No single molecular target has been confirmed, and the peptide does not bind any receptor with the selectivity typical of a conventional small-molecule drug. Mechanism therefore remains a set of hypotheses rather than an established pathway.
Laboratory work relies on standard behavioral paradigms. Rodents are tested in the elevated plus maze, open field, and passive avoidance tasks, with outcomes compared against diazepam or vehicle controls. Intranasal dosing is used most often because it bypasses first-pass metabolism, though intraperitoneal and intravenous routes also appear in published protocols. Biochemical endpoints include tissue BDNF concentrations, cytokine levels, and monoamine metabolites. Human data are limited to small Russian trials reporting reduced anxiety scores; most were not prospectively registered, and few employed independent outcome assessment.
Published work on this peptide almost always uses intranasal delivery, with drops or a spray applied to the nasal mucosa. Some animal experiments have used subcutaneous or intraperitoneal injection, and a smaller number have compared routes directly. Oral administration is not a focus of the literature, because short peptides of this size are broken down by digestive enzymes and cross intestinal barriers poorly. How much of an intranasal dose reaches the bloodstream intact in humans remains an open question.
Animal studies have examined behaviour in tests of anxiety, memory retention and stress response, and several report changes in neurotrophic or neurotransmitter-related markers. The human evidence base is much smaller, consisting mainly of short trials conducted in Russia with limited reporting in English-language journals. Sample sizes are modest and outcome measures vary between studies, so the findings are best described as preliminary. Independent replication under modern trial standards has not been widely reported.
Outside its country of origin the compound is generally handled as a research chemical rather than an approved medicine. No regulatory approval from the United States Food and Drug Administration or the European Medicines Agency has been granted for human use. Identity and purity are normally checked by reverse-phase high-performance liquid chromatography, with mass spectrometry used to confirm the molecular mass. Lyophilised material is stored cold and desiccated, and repeated freeze-thaw cycles are avoided.
Development took place at the Institute of Molecular Genetics of the Russian Academy of Sciences, where a series of short peptides were designed in the 1980s and 1990s. Selank was selected from variants of tuftsin that showed resistance to plasma peptidases. Russian regulatory approval covers it as an anxiolytic agent given intranasally. Outside that market the compound is normally handled as a research chemical rather than a medicine, and no widely recognised international pharmacopoeial monograph exists. The name Selank is a coined trade designation rather than a systematic chemical name.
Enzymatic stability motivates the extra three residues at the carboxyl end. Native tuftsin is cleaved quickly by circulating aminopeptidases and carboxypeptidases, which limits its duration of action and its usefulness as a tool compound. Extending the chain with proline-rich segments is a common design tactic because proline constrains the backbone and slows proteolysis. The same Pro-Gly-Pro motif appears in other Russian-developed peptides of the era. Whether the full seven-residue chain is required for activity, or whether it acts mainly as a prodrug releasing tuftsin, remains unresolved.
Regulatory status differs sharply by region. Selank holds a Russian marketing authorization, where it is supplied mainly as nasal drops, while authorities elsewhere have not approved it for medical use. Material sold internationally is therefore usually labeled as a research chemical rather than a medicine. Peer-reviewed publications come predominantly from Russian laboratories, and sample sizes are generally small. Whether the compound produces comparable effects under independent, well-controlled replication remains an open question that the broader literature has not settled.
Selank is a synthetic heptapeptide developed in Russia as a structural analogue of tuftsin, a naturally occurring immunomodulatory tetrapeptide. Its sequence, Thr-Lys-Pro-Arg-Pro-Gly-Pro, keeps the tuftsin core at the N-terminus and appends a Pro-Gly-Pro tail. Researchers at the Institute of Molecular Genetics in Moscow synthesized the compound during the 1990s while searching for peptides with combined anxiolytic and immunomodulatory activity. The added tail was intended to resist enzymatic cleavage and prolong the molecule's presence in circulation.
The compound has a calculated molecular weight near 751.9 daltons and carries a net positive charge at physiological pH because of its arginine residue. It dissolves freely in water and in common aqueous buffers, and typically appears as a white or off-white lyophilized powder. The amide backbone makes the molecule susceptible to peptidases, which limits oral use and favors intranasal or parenteral routes. Nomenclature in the literature varies: the substance is also described by the sequence abbreviation TP-7 and by a Russian trade designation.
The Dairy Division had been established in the Bureau of Animal Industry on July 1, 1895, and authorized by the Congress 'to collect and disseminate information relating to the dairy industry of the United States.' That was precisely and exclusively what it did until 1902, when L. A. Rogers became an employee of the Division. Rogers arrived in Washington followed by a flurry of activity. He attended his first meeting of the Society of American Bacteriologists, and with C. E. Gray was assigned an applied research project on butter, at Ames, Iowa, as animal industry staff were expected to make use of state experiment stations. When no adequate supply of milk for the research was available at Ames, the men "begged the use" of university facilities at Madison, Wisconsin. Following work in Wisconsin and Minnesota, Rogers and Gray
Root beer, originally made by Native Americans, commercialized in the United States by Charles Elmer Hires and especially popular during Prohibition Kvass, a fermented drink made from rye, popular in Eastern Europe. It has a recognizable, but low alcoholic content. Kombucha, a fermented sweetened tea. Yeast in symbiosis with acetic acid bacteria is used in its preparation. Species of yeasts found in the tea can vary, and may include: Brettanomyces bruxellensis, Candida stellata, Schizosaccharomyces pombe, Torulaspora delbrueckii and Zygosaccharomyces bailii. Also popular in Eastern Europe and some former Soviet republics under the name chajnyj grib (Russian: Чайный гриб), which means "tea mushroom". Kefir and kumis are made by fermenting milk with yeast and bacteria. Mauby (Spanish: mabí), made by fermenting sugar with the wild yeasts naturally present on the bark of the Colubrina elliptica tree, popular in the Caribbean
=== Toxicology === A method for detecting arsenious oxide, simple arsenic, in corpses was devised in 1773 by the Swedish chemist, Carl Wilhelm Scheele. His work was expanded upon, in 1806, by German chemist Valentin Ross, who learned to detect the poison in the walls of a victim's stomach. Toxicology, a subfield of forensic chemistry, focuses on detecting and identifying drugs, poisons, and other toxic substances in biological samples. Forensic toxicologists work on cases involving drug overdoses, poisoning, and substance abuse. Their work is critical in determining whether harmful substances play a role in a person's death or impairment. read more
== Society and culture == Chloral hydrate was used as one of the earliest synthetic drugs to treat insomnia. In 1912, Bayer introduced the drug phenobarbital under the brand name Luminal. In the 1930s, pentobarbital and secobarbital (better known by their original brand names Nembutal and Seconal, respectively) were synthesized. Chloral hydrate was still prescribed, although its predominance as a sedative and a hypnotic was largely eclipsed by barbiturates. Chloral hydrate is soluble in both water and ethanol, readily forming concentrated solutions. A solution of chloral hydrate in ethanol called "knockout drops" was used to prepare a Mickey Finn. In Bram Stoker's 1897 novel Dracula, the (fictional) psychiatrist John Seward is the administrator of an insane asylum in England. In his diary, he mentions his use of chloral hydrate as a sleeping aid and taking care to avoid becoming dependent, and also records the molecular formula:
Sources: en.wikipedia.org
Sodium-22 is a radioactive isotope of sodium, undergoing positron emission to 22Ne with a half-life of 2.6019 years. 22Na is being investigated as an efficient generator of "cold positrons" (antimatter) to produce muons for catalyzing fusion of deuterium. It is also commonly used as a positron source in positron annihilation spectroscopy.
Enavogliflozin (DWP16001/GCC5694A) is a selective SLC5A2 and SGLT2 inhibitor developed to treat diabetes and obesity. It was developed by GC Pharma and Daewoong Pharmaceutical. Enavogliflozin has been approved for clinical use in South Korea, and Ecuador, and applied for approval in Brazil, Mexico, Peru, and Colombia. In a meta-analysis published by Dutta et al. analysing data from 4 trials over 6 months of clinical use, enavogliflozin was well tolerated and was found to be effective for managing type 2 diabetes and may be superior to dapagliflozin with regard to certain clinical aspects
Edelman, Under Secretary of Defense for Policy, described the shelling of the Georgian villages in hearing of the United States Senate Committee on Armed Services and said that Russian peacekeepers neglected their obligation to curb artillery fire and that Georgian military began to quell artillery sites in South Ossetia on the night of 7 August. Edelman said that although Russian officials had claimed that Russia's goal was defense of Russian citizens and peacekeepers, "What became clear is there never seemed to be a limit to Russia's operational – nor strategic – aims." Edelman said that the Russian invasion was pre-planned. According to Edelman, although Putin had blamed the United States for arming Georgia, the United States had never intended for the Georgian forces to oppose Russia. Edelman further stated, "Russia was clearly adding to tension in order to provoke a Georgian response." Edelman said that the first modern Russian invasion of foreign country "sends a chilling message" about new Russian foreign policy. In September 2008, Dana Rohrabacher (a senior Republican member of the United States House of Representatives) argued at a United States House Committee on Foreign Affairs meeting that Georgia started the fighting on August 7, citing alleged unnamed intelligence reports. Telegraph noted the Russian media paid much attention to Rohrabacher's remarks. In September 2008, Senator Hillary Clinton proposed to create a U.S. commission to study the war.
Sources: en.wikipedia.org
Selank is a synthetic peptide made of seven amino acids. It is modeled on tuftsin, a natural tetrapeptide, with an added three-residue tail. It is not a small-molecule drug.
It originates from research in Russia, associated with the Institute of Molecular Genetics of the Russian Academy of Sciences. The first descriptions date to the mid-1990s. Most published studies come from Russian laboratories.
No, Selank itself does not occur naturally. Its backbone is based on tuftsin, which is produced in the body, but the seven-residue version is a synthetic construct. It is supplied as a manufactured peptide.
Reports describe modulation of GABA signalling, changes in monoamine turnover and effects on neurotrophic factor expression. These observations come mainly from animal and cell studies. A single unifying mechanism has not been demonstrated.